MX2019008445A - Calmante de dolor scn9a antisentido. - Google Patents

Calmante de dolor scn9a antisentido.

Info

Publication number
MX2019008445A
MX2019008445A MX2019008445A MX2019008445A MX2019008445A MX 2019008445 A MX2019008445 A MX 2019008445A MX 2019008445 A MX2019008445 A MX 2019008445A MX 2019008445 A MX2019008445 A MX 2019008445A MX 2019008445 A MX2019008445 A MX 2019008445A
Authority
MX
Mexico
Prior art keywords
scn9a
pain killer
exon
nucleic acid
acid derivatives
Prior art date
Application number
MX2019008445A
Other languages
English (en)
Inventor
Chung Shin
Jung Daram
Cho Bongjun
Jang Kangwon
Ju Jeon Hyun
Bae Taeyeon
Jeon Yeasel
Hwa Park Sun
Bi An Dan
Bae Jinyoung
Yeon Lee Jun
Original Assignee
Olipass Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olipass Corp filed Critical Olipass Corp
Publication of MX2019008445A publication Critical patent/MX2019008445A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/333—Modified A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a derivados de ácido nucleico peptídicos dirigidos al sitio de empalme del 3´del exón 4 en el pre-ARNm de SCN9A humana. Los derivados de ácido nucleico péptidos inducen potentemente la (s) variante (s) de empalme ARNm de SCN9A que carecen del exón 4 de SCN9A en las células, y son útiles para tratar de manera segura dolores o condiciones que involucran la actividad de Nav1.7.
MX2019008445A 2017-01-24 2018-01-23 Calmante de dolor scn9a antisentido. MX2019008445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762449738P 2017-01-24 2017-01-24
PCT/IB2018/000160 WO2018138585A1 (en) 2017-01-24 2018-01-23 Scn9a antisense pain killer

Publications (1)

Publication Number Publication Date
MX2019008445A true MX2019008445A (es) 2020-02-10

Family

ID=62979263

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008445A MX2019008445A (es) 2017-01-24 2018-01-23 Calmante de dolor scn9a antisentido.

Country Status (14)

Country Link
US (1) US11162104B2 (es)
EP (1) EP3573998A4 (es)
JP (1) JP7241019B2 (es)
KR (1) KR102592876B1 (es)
CN (1) CN110536895B (es)
AU (1) AU2018213153B2 (es)
BR (1) BR112019014689A2 (es)
CA (1) CA3051178A1 (es)
IL (1) IL267881B2 (es)
MX (1) MX2019008445A (es)
RU (1) RU2762293C2 (es)
SG (1) SG11201905601VA (es)
WO (1) WO2018138585A1 (es)
ZA (1) ZA201905064B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117624310A (zh) * 2016-12-30 2024-03-01 奥利通公司 通过肽核酸衍生物的外显子跳跃
KR102304280B1 (ko) 2018-08-14 2021-09-23 올리패스 주식회사 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드
WO2021247995A2 (en) * 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
WO2022147541A1 (en) * 2021-01-04 2022-07-07 Exicure Operating Company Compounds for modulating scn9a expression

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617422B1 (en) * 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
US9278088B2 (en) * 2002-02-19 2016-03-08 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7060723B2 (en) * 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
WO2007109324A2 (en) * 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
EP2079775A4 (en) * 2006-10-20 2011-07-27 Natureworks Llc IMAGINATED MODIFIED POLYLACTIDE RESINS
WO2009033027A2 (en) * 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
CN101480393A (zh) * 2008-01-07 2009-07-15 云南昊邦制药有限公司 草乌甲素作为制备治疗Nav1.7疼痛病症药物的应用
JP5143031B2 (ja) 2008-01-22 2013-02-13 パナソニック株式会社 光ディスクドライブ、光ディスクシステム、光ディスクシステムを搭載した移動体、プログラム、及び記録媒体
KR20090098710A (ko) * 2008-03-14 2009-09-17 주식회사 씨티아이바이오 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체
WO2009143277A2 (en) 2008-05-20 2009-11-26 Intradigm Corporation Compositions comprising hscn9a sirna and methods of use thereof
KR20110087436A (ko) 2010-01-26 2011-08-03 주식회사 씨티아이바이오 전위차 나트륨 이온 채널 아형 9(에스씨엔 9에이)의 안티센스 올리고핵산
RU2588654C2 (ru) * 2010-06-23 2016-07-10 Курна, Инк. Лечение заболеваний, связанных с альфа-субъединицей потенциалзависимого натриевого канала (scna), путем ингибирования природного антисмыслового транскрипта гена scna
JP2014509859A (ja) * 2011-03-16 2014-04-24 アムジエン・インコーポレーテツド １７ｎａｖ１．３およびｎａｖ１．７の強力かつ選択的阻害剤
TWI642438B (zh) * 2011-06-24 2018-12-01 可娜公司 藉由抑制電壓門控鈉離子通道α次單元（ＳＣＮＡ）之天然反義轉錄物治療ＳＣＮＡ相關疾病
CA3032549A1 (en) 2016-08-08 2018-02-15 Olipass Corporation Androgen receptor antisense oligonucleotides
RU2748834C2 (ru) 2016-09-16 2021-05-31 Олипасс Корпорейшн Антисмысловые олигонуклеотиды против scn9a
CN117624310A (zh) 2016-12-30 2024-03-01 奥利通公司 通过肽核酸衍生物的外显子跳跃

Also Published As

Publication number Publication date
JP7241019B2 (ja) 2023-03-16
CN110536895B (zh) 2023-10-20
AU2018213153B2 (en) 2021-04-01
WO2018138585A1 (en) 2018-08-02
IL267881B1 (en) 2023-11-01
US11162104B2 (en) 2021-11-02
US20190338292A1 (en) 2019-11-07
ZA201905064B (en) 2022-10-26
SG11201905601VA (en) 2019-08-27
RU2019125286A (ru) 2021-02-26
EP3573998A4 (en) 2020-12-16
BR112019014689A2 (pt) 2020-02-18
IL267881B2 (en) 2024-03-01
IL267881A (en) 2019-09-26
RU2762293C2 (ru) 2021-12-17
AU2018213153A1 (en) 2019-08-15
RU2019125286A3 (es) 2021-05-14
EP3573998A1 (en) 2019-12-04
KR20190103372A (ko) 2019-09-04
KR102592876B1 (ko) 2023-10-23
CN110536895A (zh) 2019-12-03
CA3051178A1 (en) 2018-08-02
JP2020506686A (ja) 2020-03-05

Similar Documents

Publication Publication Date Title
MX2019008445A (es) Calmante de dolor scn9a antisentido.
EP3800255A3 (en) Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
EA201991255A1 (ru) Регулируемая транскрипция
SG11202003692YA (en) Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
NZ747685A (en) Oligonucleotide analogues targeting human lmna
MX2020011786A (es) Oligomeros antisentido para tratamiento de afecciones y enfermedades.
MX2023006467A (es) Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos.
CL2019000732A1 (es) Tratamiento avv de la enfermedad de huntington.
EP4166667A3 (en) Compositions for modulating c9orf72 expression
NZ733882A (en) Compositions for modulating c9orf72 expression
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
WO2013086444A3 (en) Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
IN2012DN03824A (es)
MX342001B (es) Tratamiento de artritis por lupus usando laquinimod.
BR112015010955A2 (pt) inibidores de glutaminase heterocíclica
BR112019002387A2 (pt) oligonucleotídeos antissenso de receptor de andrógeno
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
NZ737871A (en) Electroporation system for controlled localized therapeutics delivery
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
Markelc et al. Inhibitor of endocytosis impairs gene electrotransfer to mouse muscle in vivo
EA202091693A1 (ru) Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
WO2012014081A3 (en) Use of a composition comprising a peptidic fava bean extract for the stimulation of hair growth
CY1123639T1 (el) Μονοκλωνα ολιγονουκλεοτιδια για χρηση στην ιατρικη θεραπευτικη αντιμετωπιση διαταραχων του δερματος
MX2020007433A (es) Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos.
NZ741841A (en) Antisense oligonucleotides for use in treating alzheimer’s disease